Sir, A patient in their mid-40s with a past history of type 2 diabetes, hypertension, hepatitis C with cirrhosis, COPD, cocaine abuse and subarachnoid haemorrhage with a ventriculoperitoneal shunt presented to the emergency department with shortness of breath and altered mental status. Vital signs were notable for a normal temperature, heart rate of 62 bpm, respiratory rate of 20 breaths/min and a blood pressure of 130/60 mmHg. On examination, the patient was alert, but not oriented; however, the patient was able to follow simple commands. The patient did not exhibit clear meningeal signs and had no focal deficits. Cardiovascular examination was significant for III/VI holosystolic murmur across the precordium, and jugular venous distension. The urine drug screen was positive for cocaine, cannabis and opiates. Initial labs were significant for metabolic acidosis, leucocytosis, hyponatraemia, hyperglycaemia and mild troponin elevation. CT of the head showed a chronic subarachnoid haemorrhage along the shunt tract, chest CT without contrast demonstrated bilateral lower lobe infiltrate and small bilateral pleural effusions and CT of the abdomen was significant for liver cirrhosis with signs of portal hypertension.
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The patient was started empirically on vancomycin and cefepime. Transthoracic echocardiogram revealed a normal size left ventricle with normal systolic function. Systolic anterior motion of the anterior leaflet of the mitral valve was present with dense posterior mitral annular calcifications and mild mitral regurgitation. The patient was intubated for airway protection and a transesophageal echocardiogram (TEE) was requested. In the interim the ECG was noted to progress from normal sinus rhythm to complete heart block and subsequently an urgent temporary venous pacemaker was placed. TEE showed a large vegetation on the mitral valve, measuring 2.82 % 0.7 cm. The posterior leaflet appeared to be perforated and severe mitral regurgitation was also noted. The initial blood cultures drawn on day 1 of admission were positive for MRSA with an MIC of vancomycin of 2 mg/L. Due to the relatively high MIC and the risk of clinical failure, vancomycin therapy was changed to 10 mg/kg daptomycin every 48 h adjusted for renal dysfunction on day 3 of admission. Cardiothoracic surgery staff evaluated the patient, who was declared a poor surgical candidate, with a potentially fatal surgical outcome given multiple comorbidities. Blood cultures continued to grow MRSA on days 3, 5 and 6, and the patient progressed to septic shock despite treatment with daptomycin. Given the persistent bacteraemia despite 3 days of daptomycin therapy, 600 mg of ceftaroline every 8 h adjusted for continuous renal replacement therapy was added on day 6 of hospitalization. Blood cultures on day 8 following the addition of ceftaroline to daptomycin were negative for MRSA. The addition of rifampicin in combination therapy with daptomycin was considered, but not chosen secondary to the patient's liver insufficiency and the risk of hepatotoxicity with rifampicin. Fosfomycin was also considered for combination therapy, but not chosen secondary to administration of high-dose norepinephrine and fixed-dose vasopressin and the risk of decreased oral absorption.
Refractory MRSA bacteraemia is a challenging infection that poses an increased risk of poor patient outcomes and large healthcare resource utilization.
1,2 The only antibiotics approved by the US FDA for the treatment of MRSA bacteraemia are vancomycin and daptomycin. Ceftaroline fosamil is a fifth-generation cephalosporin that binds to PBPs with high affinity for PBP2a to overcome methicillin resistance and also inhibits cell-wall synthesis. It has demonstrated its bactericidal activity against MRSA with a susceptibility breakpoint 1 mg/L for skin and soft-tissue infection. 3, 4 Pathogens can resist eradication in the absence or presence of bacterial resistance despite appropriate antibiotic therapy. Hence, further options such as combination therapy including b-lactam antibiotics have been explored and described. 5, 6 The utilization of combination therapy including daptomycin and ceftaroline has demonstrated considerable synergy. Sakoulas et al. 5 described 26 patients with persistent staphylococcal bacteraemia in which daptomycin and ceftaroline combination therapy was administered. Ten cases of persistent MRSA bacteraemia secondary to native valve endocarditis failed vancomycin therapy. Fifty percent of these patients also failed subsequent therapy with daptomycin. Daptomycin dosing ranged from 6 to 10 mg/kg/dose and ceftaroline dosing ranged from 600 to 1800 mg/day in divided doses. Bacteraemia in all patients with endocarditis cleared in a median of 2 days (range"1-6 days) of initiation of combination therapy. Barber et al. 7 recently described an in vitro simulation using two clinical daptomycin-non-susceptible MRSA isolates. This simulation demonstrated that the combination therapy is highly bactericidal against MRSA strains with reduced susceptibility to daptomycin. When combination therapy (600 mg of ceftaroline every 12 h and V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. 6 or 10 mg/kg/day daptomycin) was de-escalated to a singleagent therapy at 96 h, the growth suppression was maintained up to 192 h regardless of initial daptomycin dose. However, some case reports describe the failure of daptomycin therapy alone despite the initial eradication of bacteraemia in endocarditis. 5 Due to the high-inoculum effect and the critical nature of MRSA infective endocarditis, de-escalation of combination therapy should be done with caution. Although ceftaroline is not approved by the FDA for the treatment of endocarditis, the decision was made collectively for our patient to continue the combination therapy for 6 weeks due to the persistent bacteraemia before the combination therapy, inability to achieve source control and high risk for poor outcome due to multiple comorbidities. Further research and clinical cases are warranted for de-escalation timing and optimal dosing.
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